Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Oncology drug sponsors who seek FDA accelerated approval based upon single-arm studies run the risk of a “refuse-to-file” letter, a new analysis suggests.
Advertisement

Related Content

Novartis Previews Panobinostat PFS Advantage In Myeloma
Randomization Required: Liver Signal Necessitated Kadcyla Trial With Control Arm
Erivedge Efficacy Overcomes Limitations Of Single-Arm Study
Onyx’s Myeloma Drug Kyprolis Fits ODAC’s View On Accelerated Approval
Onyx Shifts Priorities Away From JAK Inhibitors, Puts More Emphasis on Carfilzomib
FDA Sends Back Filing For Pfizer's Tafamidis, Acquired in FoldRx Deal
FDA Sends Back Filing For Pfizer's Tafamidis, Acquired in FoldRx Deal
RE-LY Study Oversight Weaknesses A Factor In Pradaxa “Refuse-To-File” Action
Accelerated And Accompanied: Oncology Drugs Should Use Randomized Trials, FDA Panel Says
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

Topics

Advertisement
UsernamePublicRestriction

Register

PS004743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel